ESMO 2017: Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases

Madrid, Spain ( Bone metastases occur in 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with symptomatic skeletal events (SREs), as well as worse outcomes with vascular-endothelial growth factor (VEGF)-targeted agents.
Page 3 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.